Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform – Insights From The Discussion
MELVILLE, NY / ACCESSWIRE / July 31, 2023 / Chronic back pain is a significant issue in the United States,...
Disability
Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome
Independent Data Monitoring Committee recommended REVEAL Phase 1/2 trial continuation and proceeding with dosing of second patient based on encouraging...
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned
ATH434-201 Trial on Track to Complete Enrollment in Q3 2023 Top-Line Data Expected by the End of 2024 MELBOURNE, Australia...
Nalu Medical, Inc. Presents Important New Clinical Data for PNS and SCS at ASPN 2023
CARLSBAD, Calif.--(BUSINESS WIRE)--Nalu Medical, Inc. (“Nalu”), a Carlsbad, California-based neurostimulation company that has miniaturized neurostimulation implants for the management of...
Relievant Medsystems Announces Pooled 4-Year Outcomes Validating Long-Term Effectiveness of the Intracept Procedure
Findings, Presented at Annual American Society of Pain & Neuroscience Conference, Demonstrate Significant and Durable Relief of Chronic Vertebrogenic Low...
VidaTalk’s Talk-to-Translate Feature Will Have a Transformative Impact on Hospitalized Patients With Language Barriers
Achieving the standard of care, no matter the language or disability.ANN ARBOR, MI / ACCESSWIRE / July 19, 2023 /...
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE(R) in the U.S. with Pentec Health
Recent Pentech Health acquisition of ZOIA Pharma broadens distribution and access for patients to PKU GOLIKE®GENEVA, SWITZERLAND / ACCESSWIRE /...
George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2
George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2 All patients enrolled...
First of its kind study into digital self-management support for autistic adults reveals significant improvements in anxiety levels and quality of life
Clinical study by Cornwall NHS Trust and University of Plymouth finds anxiety, self-injurious behaviour, memory, and orientation problems are reduced...
MIMEDX Appoints Doug Rice as Chief Financial Officer
Company adds seasoned MedTech CFO to leadership teamMARIETTA, Ga., July 05, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG)...
Celularity Announces Presentation at Upcoming 7th International Conference on Orthopedics
Data will be presented from an in vitro study of decellularized-flowable placental connective tissue matrix supporting cellular functions of human...
Long-term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX®2-73 (blarcamesine) for Rett Syndrome
NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
DepYmed Presents Development Update for its Small Molecule PTP1B Inhibitor Program, DPM-1003, at the 2023 IRSF Rett Syndrome Scientific Meeting
Data were presented to demonstrate that DPM-1003 provides a mechanism-based approach to the treatment of Rett Syndrome and is poised...
Relievant Medsystems Announces Pooled Three-Year Outcomes from Intracept Procedure that Demonstrate Long-Term Pain Relief and Reduced Opioid Use in Chronic Vertebrogenic Low Back Pain Patients
MINNEAPOLIS, June 15, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic...
Anavex Life Sciences Announces Completion of ANAVEX(®)2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
NEW YORK, June 06, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke
In a preclinical model of ischemic stroke, systemic delivery of a selective Fzd4 Wnt antibody strongly reduced blood-brain-barrier leakage, death...
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome
The Phase 1/2 REVEAL trial is a first-in-human, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of...
Canadians Gear up for annual MS Bike Event Series in Support of People Living with Multiple Sclerosis
MS Canada’s cycling fundraising event series is back this June featuring road bike tours across 12 Canadian communities, bringing people...
MS Canada Joins Global Efforts on World MS Day to Foster Connection and Advance MS Research and Awareness
TORONTO, May 30, 2023 (GLOBE NEWSWIRE) -- MS Canada, the country’s leading organization in multiple sclerosis (MS) research and advocacy...
Thousands of Canadians Coast to Coast Walk Together In Support of Those Affected by Multiple Sclerosis
TORONTO, May 24, 2023 (GLOBE NEWSWIRE) -- On May 28, Canadians coast to coast will come together to take part...